mCRPC VL

Journal Club: Final OS Analysis of COU-AA-302 - Abiraterone in mCRPC without Prior Chemo - Charles Ryan

Details
Journal Club: Final OS Analysis of COU-AA-302 - Study of Abiraterone Acetate in mCRPC without Prior Chemo Charles Ryan, MD discusses the preservation of function, the prevention of symptoms, and the prolongation of overall survival from this final analysis of the COU-AA-302 study abiraterone to prednisone in chemotherapy-naive mCRPC patients. Charles J. Ryan, MD Professor of Clinical Medicine Divi...

Radiographic Progression-free Survival as a Response Biomarker in mCRPC: COU-AA-302 Results - Charles Ryan

Details
Prostate Cancer Journal Club - Radiographic Progression-free Survival as a Response Biomarker in Metastatic Castration-resistant Prostate Cancer: COU-AA-302 Result Charles Ryan, MD discusses the results of a randomized trial of mCRPC patients which showed that radiographic PFS was highly consistent and highly associated with overall survival. Charles J. Ryan, MD Professor of Clinical Medicine Divi...

Alicia Morgans on Transitions in Treating mCRPC: Abiraterone after Sipuleucel-T

Details
Transitions in Treating mCRPC: Abiraterone after Sipuleucel-T Alicia Morgans, MD presents the treatment of a prostate cancer patient throughout a period of disease progression, and provides the rationale for patient selection and drug selection for treatments. Alicia K. Morgans, MD Assistant Professor of Medicine Vanderbilt University Medical Center

Selection of Systemic Therapy: Chemotherapy and Androgen Axis Agents - Evan Yu

Details
Selection of Systemic Therapy: Chemotherapy and Androgen Axis Agents Evan Yu, MD compares data from the CHAARTED and GETUG-AFU 15 trials, including safety and toxicity considerations, and discusses which patients should receive docetaxel. Evan Y. Yu, MD Associate Professor of Medicine (Oncology) University of Washington Fred Hutchinson Cancer Research Center SEE RELATED CONTENT Insights into E3805...

Lower Tumor Burden Patient with Progression after Sipuleucel-T, Treated with Abiraterone Acetate - Charles Ryan

Details
Lower Tumor Burden Patient with Progression after Sipuleucel-T, Treated with Abiraterone Acetate Charles Ryan, MD presents a case study of a prostate cancer patient with lower tumor burden associated with disease progression after sipuleucel-T, and then treated with abiraterone acetate. Charles J. Ryan, MD Professor of Clinical Medicine Division of Hematology / Oncology Helen Diller Family Compreh...

Thomas Keane on NCCN Guidelines Update - 2015

Details
NCCN Guidelines Update - 2015 Tom Keane, MBBCh, FRCSI, FACS highlights recent changes to the National Comprehensive Cancer Network guidelines for prostate cancer, including a reorganization of the algorithm for castration-resistant prostate cancer, the inclusion of molecular testing and the addition of new technology for bone scans. Thomas E. Keane, MBBCh, FRCSI, FACS Professor and Chairman of the...

Final OS Analysis of COU-AA-302 - Study of Abiraterone Acetate in mCRPC without Prior Chemo - Charles Ryan

Details
Final Overall Survival Analysis of COU-AA-302, a Randomized Phase 3 Study of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients without Prior Chemotherapy Charles Ryan, MD presents a final analysis of the COU-AA-302 study which has demonstrated a statistically significant improvement in overall survival in mCRPC patients who have not had prior exposure to chemotherapy....

Understanding Antigen Spreading in Immunotherapy

Details
Understanding the Concept of Antigen Spreading in Immunotherapy Leonard Gomella, MD explains how immunotherapy is becoming more commonplace in the management of malignant disease, the basic mechanisms of the immune response, and how the concept of antigen spreading may explain the anti-tumor effects of some of our newer immunotherapies. Leonard G. Gomella, MD, FACS Thomas Jefferson University Hosp...

Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive mPrCa

Details
Chemohormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer Christopher Sweeney, MD presents the results of the CHAARTED trial, which looked at the effects of adding docetaxel chemotherapy at the time of commencement of androgen deprivation therapy (ADT) in men with mCRPC. Christopher Sweeney, MD Dana-Farber Cancer Institute RELATED CONTENT Listen to an...

The Art and Science of Treating Men with CRPC

Details
The Art and Science of Treating Men with Castration-resistant Prostate Cancer Paul Sieber, MD presents two mCRPC patient cases and demonstrates the individualized treatment process of care unique to each patient. Paul R. Sieber, MD, FACS Lancaster Urology